RNA interference with zilebesiran for mild to moderate hypertension
About The Study: In adults with mild to moderate hypertension, treatment with zilebesiran, an investigational RNA interference therapeutic, across a range of subcutaneous doses at 3-month or 6-month intervals significantly reduced 24-hour mean ambulatory systolic blood pressure at month three in this phase 2, randomized clinical trial.
Authors: George L. Bakris, M.D., of University of Chicago Medicine, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2024.0728)
Editor’s ...










